Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile at single cell level of non-malignant cells in KRAS syngeneic mouse tumor models

ABSTRACT: Gene expression profile at single cell level of non-malignant cells in KRAS syngeneic mouse tumor models

PROVIDER: PRJNA967598 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24443330.fastq.gz	Fastqsanger.gz
	SRR24443331.fastq.gz	Fastqsanger.gz
	SRR24443332.fastq.gz	Fastqsanger.gz
	SRR24443333.fastq.gz	Fastqsanger.gz
	SRR24443334.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 11

Similar Datasets

Gene expression profile at single cell level of non-malignant cells in KRAS syngeneic mouse tumor models

Project description:STK11/LKB1 mutation is a primary driver for immunotherapy resistance. We employed KRAS/LKB1 syngeneic mouse models by injecting tumor cells with Kras mutation, Kras/Stk11 mutation and MCT4 knockout. We used single-cell RNA-seq to analyze the impact of LKB1 deficiency on the immune microenvironment.

2023-05-10 | GSE231742 | GEO

Proteomics of Mouse Syngeneic Models

Project description:The cell line-derived xenografts and patient derived xenografts have limited use in cancer immunotherapy evaluation because an immune compromised host is required for xenotransplantation. Syngeneic mouse models are derived by transplanting established mouse cell lines or tumor tissues to strain matched mouse hosts, which are better suited to study the interplay between immune and tumor cells. We investigated the differences as well as similarities of a panel of ten mouse syngeneic models to features of human tumors by proteomics, which will provide valuable information to assist experimental biologists in model selection.

2019-12-03 | PXD011885 | Pride

Gene expression profile at single cell level of non-malignant cells in KRAS syngeniec mouse tumor models harboring STK11 and/or KEAP1 co-muation

Project description:STK11/LKB1 and KEAP1 mutations are associated with immunotherapy resistance. We employed KRAS syngeneic mouse cells (K) and generated KEAP1 loss (KK) or STK11/KEAP1 loss (KLK) by CRISPR/KO. Then we injected these tumor cells and collected the tumor for single-cell RNA-seq. Our aim is to analyze the impact of STK11 and/or KEAP1 deficiency on the immune microenvironment.

2024-05-20 | GSE267321 | GEO

Single cell sequencing of mouse syngeneic tumor models

Project description:Single cell sequencing of mouse syngeneic tumor models

| PRJNA498671 | ENA

Differential expression of murine syngeneic orthotopic glioblastoma tumour models

Project description:Bulk RNA sequencing analysis of murine syngeneic orthotopic GL261-luc2 and CT2A-luc glioblastoma tumour models

2023-11-01 | GSE215123 | GEO

Gene expression profile at single cell level of non-malignant cells in KRAS syngeniec mouse tumor models harboring STK11 and/or KEAP1 co-muation

Project description:Gene expression profile at single cell level of non-malignant cells in KRAS syngeniec mouse tumor models harboring STK11 and/or KEAP1 co-muation

| PRJNA1111059 | ENA

Differential expression of murine syngeneic orthotopic glioblastoma tumour models

Project description:Differential expression of murine syngeneic orthotopic glioblastoma tumour models

| PRJNA888952 | ENA

Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery [aCGH]

Project description:Murine syngeneic tumor models are the cornerstone of novel immuno-oncology (IO)-based therapy development but the molecular and immunological features of these models are still not clearly defined. The translational relevance of differences between the models is not fully understood, impeding appropriate preclinical model selection for target validation, and ultimately hindering drug development. Within a panel of commonly-used murine syngeneic tumor models, we showed variable responsiveness to IO-therapies. We employed aCGH, whole-exome sequencing, exon microarray analysis and flow cytometry to extensively characterise these models and revealed striking differences that may underlie these contrasting response profiles. We identified strong differential gene expression in immune-related pathways and changes in immune cell-specific genes that suggested differences in tumor immune infiltrates between models. We further investigated this using flow cytometry, which showed differences in both the composition and magnitude of the tumor immune infiltrates, identifying models that harbor ‘inflamed’ and ‘non-inflamed’ tumor immune infiltrate phenotypes. Moreover, we found that immunosuppressive cell types predominated in syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, whereas cytotoxic effector immune cells were enriched in responsive models. A cytotoxic cell-rich tumor immune infiltrate has been correlated with increased efficacy of IO-therapy in the clinic and these differences could underlie the varying response profiles to IO-therapy between the syngeneic models. This characterisation highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of IO-therapies as well as combinations with targeted therapies in vivo.

2016-12-07 | GSE85508 | GEO

Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery [exon array]

2016-12-07 | GSE85507 | GEO

Characterisation of murine syngeneic tumor models

Project description:Characterisation of murine syngeneic tumor models enables rational preclinical model selection for immuno-oncology drug discovery

| PRJEB12925 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data